Drug intelligence / Profile preview

conjugated equine estrogens + fenretinide

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of conjugated equine estrogens (CEE) and fenretinide. CEE is a natural formulation extracted from pregnant mares' urine containing multiple estrogens used primarily for managing menopausal symptoms and preventing osteoporosis. Fenretinide is a synthetic retinoid derivative that has been investigated for cancer prevention, particularly breast cancer. The combination has been studied in clinical trials for its effects on cardiovascular risk biomarkers and potential breast cancer prevention in postmenopausal women.

Other names: CEE + fenretinide

Targets

ER (Estrogen receptor)RAR (Retinoic acid receptor)

Beyond the preview

Go deeper on conjugated equine estrogens + fenretinide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on conjugated equine estrogens + fenretinide.

Explore the full profile